Collagen production process

The combination of a recombinant collagen fragment and a hydrophobic amino acid in a spray drying process addresses the challenges of collagen stability and flow characteristics, producing a stable, water-soluble powder with enhanced properties.

WO2024238910A1PCT designated stage expired Publication Date: 2024-11-21HTL BIOTECHNOLOGY INNOVATION INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/029916
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing methods for spray drying collagen, such as animal-derived collagen, face challenges in controlling particle properties and process yields due to adhesiveness and moisture content, leading to instability and poor flow characteristics in the final product.

Method used

A spray dried composition comprising a recombinant collagen fragment with a sequence identity of at least 85% to a specific amino acid sequence, combined with a hydrophobic amino acid like leucine, is developed, which is processed through an aqueous mixture, filtration, and spray drying, potentially including pasteurization, to create a stable and flowable powder.

Benefits of technology

The approach results in a stable, water-soluble powder with improved flow characteristics and extended shelf life, eliminating the need for additional excipients and maintaining product integrity, as demonstrated by Size Exclusion Chromatography and angle of repose measurements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000017_0001
    Figure IMGF000017_0001
  • Figure 00000022_0000
    Figure 00000022_0000
Patent Text Reader

Abstract

The present disclosure relates to powder compositions comprising a recombinant collagens and hydrophobic amino acids and processes for preparing such compositions. Methods of using the compositions described herein are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

COLLAGEN PRODUCTION PROCESSREFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0001] The content of the electronically submitted sequence listing in ASCII text file (Name: 4431_102PC01_SequenceListing_ST26; Size: 2,868 bytes; and Date of Creation: May 15, 2024) filed with the application is incorporated herein by reference in its entirety.BACKGROUND

[0002] Collagen is one of the most important proteins in the human body and is present in connective tissue such as cartilage, bones, tendons, ligaments, and skin, and it is the major protein in the extra-cellular matrix of human cells. Animal-derived collagen is frequently used as an active ingredient in the medical and cosmetic fields, for example as a component of tissue grafts and topical skin treatments.

[0003] Spray drying is commonly used in the art to extend the stability and chemical integrity of valuable active ingredients as dry formulations typically demonstrate improved stability, prolonged shelf life, and lower transportation costs relatively to their solvated counterparts.

[0004] While spray drying provides numerous advantages, this common technology cannot always be readily adapted to every active ingredient or formulation. For example, it is often difficult to control particle properties (such as particle size and particle morphology) and process yields, due to adhesiveness and moisture content in the powder resulting from the spray drying process. Accordingly, there remains a need for processes for preparing certain spray dried active ingredients, such as collagen, that maintain high yield and product integrity. There is likewise a need for spray dried collagen products having suitable flow characteristics and appearance.BRIEF SUMMARY

[0005] The present disclosure provides a spray dried composition comprising a recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1, and a hydrophobic amino acid, whereinthe composition is a powder. In some embodiments, the recombinant collagen fragment is unhydroxylated. In some embodiments, the recombinant collagen fragment is hydroxylated.

[0006] In some embodiments, the hydrophobic amino acid and the recombinant collagen fragment are present in the composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 5:95. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 10:90. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 15:85. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 20:80.

[0007] In some embodiments, the hydrophobic amino acid is leucine. In some embodiments, the leucine and the recombinant collagen fragment are present in the composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt). In some embodiments, the ratio of the leucine to the recombinant collagen fragment is about 5:95. In some embodiments, the ratio of the leucine to the recombinant collagen fragment is about 10:90. In some embodiments, the ratio of the leucine to the recombinant collagen fragment is about 15:85. In some embodiments, the ratio of the leucine to the recombinant collagen fragment is about 20:80.

[0008] In some embodiments, the hydrophobic amino acid is selected from the group consisting of isoleucine, leucine, valine, and phenylalanine. In some embodiments, the hydrophobic amino acid is isoleucine. In some embodiments, the hydrophobic amino acid is valine. In some embodiments, the hydrophobic amino acid is phenylalanine.

[0009] In some embodiments, the spray dried powder is water soluble at room temperature. In some embodiments, the spray dried powder further comprises a flow agent. In some embodiments, the spray dried powder does not comprise a flow agent. In some embodiments, the composition further comprises a preservative. In some embodiments, the preservative is potassium sorbate. In some embodiments, the preservative is sodium benzoate. In some embodiments, the composition comprises a pH-adjusting agent. In some embodiments, the pH-adjusting agent is citric acid.

[0010] In some embodiments, the powder has an angle of repose of about 30° to about 60°. In some embodiments, the powder has an angle of repose of about 48.5°. In some embodiments, the powder has an angle of repose of about 50°.

[0011] In some embodiments, the present disclosure provides a process for preparing the spray dried composition of claim 1, comprising: a) preparing an aqueous mixture comprising the recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1, the hydrophobic amino acid, and deionized water, to form a feed solution; b) filtering the feed solution through a filter to form a filtered solution; and c) spray drying the filtered solution to form the powder. In some embodiments, the process further comprises pasteurization.

[0012] In some embodiments, the hydrophobic amino acid and the recombinant collagen fragment are present in the spray dried composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 5:95. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 10:90. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 15:85. In some embodiments, the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 20:80.

[0013] Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure.

[0014] It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and do not restrict the scope of the claims.BRIEF DESCRIPTION OF THE FIGURES

[0015] FIGS. 1A-1B are Size Exclusion Chromatography (SEC) graphs showing peak profiles of 1) a composition comprising a recombinant collagen fragment and leucine before spray drying (“spray drying feed solution”); and 2) the same composition after spray drying (“spray dried product”).

[0016] FIG. 1A shows peak profiles from a mixture with a 20:80 (wt / wt) ratio of leucine to recombinant collagen.

[0017] FIG. IB shows peak profiles from a mixture with a 15:85 (wt / wt) ratio of leucine to recombinant collagen.DETAILED DESCRIPTION

[0018] The headings provided herein are not limitations of the various embodiments of the disclosure, which can be defined by reference to the specification as a whole. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.Definitions

[0019] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed technology, because the scope of the technology is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification will control.

[0020] The indefinite articles “a” and “an” to describe an element or component means that one or at least one of these elements or components is present. Although these articles are conventionally employed to signify that the modified noun is a singular noun, as used herein the articles “a” and “an” also include the plural, unless otherwise stated in specific instances. Similarly, the definite article “the,” as used herein, also signifies that the modified noun can be singular or plural, again unless otherwise stated in specific instances.

[0021] As used herein, the term “about” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, ie., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 10% (e.g., up to 10%, up to 5%, or up to 1%) of a given value.

[0022] The term “at least” prior to a number or series of numbers is understood to include the number associated with the term “at least,” and all subsequent numbers or integers thatcould logically be included, as clear from context. When at least is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range. For example, “at least 3” means at least 3, at least 4, at least 5, etc. When at least is present before a component in a method step, then that component is included in the step, whereas additional components are optional.

[0023] As used herein, the terms “comprises,” “comprising,” “having,” “including,” “containing,” and the like are open-ended terms meaning “including, but not limited to.” To the extent a given embodiment disclosed herein “comprises” certain elements, it should be understood that present disclosure also specifically contemplates and discloses embodiments that “consist essentially of’ those elements and that “consist of’ those elements.

[0024] As used herein the terms “consists essentially of,” “consisting essentially of,” and the like are to be construed as a semi-closed terms, meaning that no other ingredients which materially affect the basic and novel characteristics of an embodiment are included.

[0025] As used herein, the terms “consists of,” “consisting of,” and the like are to be construed as closed terms, such that an embodiment “consisting of’ a particular set of elements excludes any element, step, or ingredient not specified in the embodiment.

[0026] As used herein, the term “measure” and variations thereof can encompass the meaning of a respective term, such as “determine,” “calculate,” and variations thereof.

[0027] The term “modified,” as applied to the collagens and collagen fragments refers to collagen fragments comprising an amino acid sequence that is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 80%, 90%, 91%, 92%, 93%, 94% 95%, 96%, 97%, 98%, or 99% identical or similar to the amino acid sequence of a biologically active molecule. In some embodiments, the modified collagen fragment comprises an amino acid sequence that is at least 40%, 45%, 50%, 55%, 60%, 65%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of a native or previously engineered sequence. The modified sequence can comprise additions, deletions, substitutions, or a combination thereof to the amino acid sequence of a native or previously engineered molecule. For example, a modified collagen fragment can incorporate or delete 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues compared to a native collagen sequence. Such selections can be made to modify the looseness or tightness of a recombinant collagen. The degree of hydroxylation of collagen correlates with the looseness or tightness of the collagen triple helix. A modified collagen fragment can alsoinclude chemical modifications to a polypeptide, such as crosslinks between cysteine residues, or hydroxylated or glycosylated residues. As used herein, the terms “variant” and “sequence variant” refer to a polypeptide sequence that is about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO: 1.

[0028] The terms “pharmaceutically acceptable” and “cosmetically acceptable,” as applied to carriers, excipients, or stabilizers that can be used in the compositions described herein, refer to carriers, excipients, or stabilizers that are nontoxic to recipients at the dosages and concentrations employed.

[0029] As used herein, “solubility” refers to the amount of a substance that dissolves in a given volume of solvent at a specified temperature and pH, e.g., to form a saturated solution. Solubility can be determined, for example, using the shake-flask solubility method (ASTM: E 1148-02, Standard Test Method for Measurements of Aqueous Solubility, Book of Standards Volume 11.05). Solubility can be determined at any pH. Solubility can be tested at any temperature between 20 °C and 40 °C. For example, solubility can be determined at approximately pH 7.0-7.4 and approximately 37 °C.A. Collagen

[0030] The term "collagen" refers to any one of the known collagen types, including collagen types I through XXVIII, as well as to any other collagens, whether natural, synthetic, semi -synthetic, or recombinant. The term collagen includes collagen, collagen fragments, collagen-like proteins, triple helical collagen, alpha chains, monomers, gelatin, trimers and combinations thereof. As used herein, collagen is a generic term for a family of at least 28 distinct collagen types.

[0031] Collagen has a distinctive amino acid composition; nearly one-third of its amino acid residues are glycine; another 15% to 30% are proline or 4-hydroxyproline (Hyp) residues. Hydroxylysine is also characteristic of collagen. These hydroxylated amino acid residues, which are formed as the result of posttranslational modification, confer stability on collagen through intramolecular hydrogen bonds involving bridging water molecules. The collagen content in a tissue can be determined by measurement of its hydroxyproline content. Hydroxyproline content can be measured by methods known in the art, for example by liquid chromatography-mass spectrometry (LC-MS). Collagen contains many repeatediterations of the sequence Gly-X-Y, where X is often proline and Y is often 4- hydroxyproline.

[0032] Collagen variants containing such amino acid residue substitutions can be produced by a variety of known methods, including genetic engineering techniques and in vitro peptide synthesis. Collagen variants can also be produced by varying the amount of hydroxylysines and / or hydroxyprolines present in a given molecule, by the varied expression of lysine hydroxylases, and / or proline hydroxylases, wherein the hydroxylase genes (recombinant or otherwise) are expressed in a host cell for the expression of recombinant collagen, or derivatives thereof. Hydroxyproline content can be measured by methods known in the art, for example by liquid chromatography -mass spectrometry (LC- MS).

[0033] Any type of collagen, including Collagen Types I through XXVIII are suitable for use in the compositions and processes described herein.B. Recombinant Collagen and Recombinant Collagen Fragments

[0034] As used herein, the term “recombinant collagen” refers to the family of at least 28 distinct naturally occurring collagen types including, but not limited to collagen types I through XXVIII, prepared using recombinant techniques.

[0035] In some embodiments, the recombinant collagen described herein can be a recombinant collagen fragment. A recombinant collagen fragment can be a fragment of the full amino acid sequence of a native collagen molecule capable of forming tropocollagen (trimeric collagen) or the fragment can be a fragment of a modified collagen molecule or truncated collagen molecule having an amino acid sequence at least 70, 80, 90, 95, 96, 97, 98, or 99% identical or similar to a native collagen amino acid sequence (or to a fibril forming region thereof or to a segment substantially comprising [Gly-X-Y]n). In particular embodiments, the term recombinant collagen refers to a recombinant collagen of any known type, including those described in PCT / US2022 / 027016, the entirety of which is incorporated herein by reference.

[0036] In some embodiments, the collagen fragment described herein can have an amino acid sequence according to SEQ ID NO: 1. In some instances, the collagen fragment described herein can have an amino acid sequence according to SEQ ID NO: 1. In some embodiments, the collagen fragment can have at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about70%, at least about 75%, at least about 80%, about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 9%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity, or similarity, to SEQ ID NO: 1.

[0037] The amino acid sequence of SEQ ID NO: 1 is: DVKSGVAVGGLAGYPGPAGPPGPPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSG PPGPPGAIGPSGPAGKDGESGRPGRPGERGLPGPPGIKGPAGIPGFPGMKGHRGFD GRNGEKGETGAPGLKGENGLPGENGAPGPMGPRGAPGERGRPGLPGAAGARGN DGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPGSNGAPGQRGEPGPQGH AGAQGPPGPPGINGSPGGKGEMGPAGIPGAPGLMGARGPPGPAGANGAPGLRGG AGEPGKNGAKGEPGPRGERGEAGIPGVPGAKGEDGKDGSPGEPGANGLPGAAG ERGAPGFRGPAGPNGIPGEKGPAGERGAPGPAGPRGAAGEPGRDGVPGGPGMRG MPGSPGGPGSDGKPGPPGSQGESGRPGPPGPSGPRGQPGVMGFPGPKGNDGAPG KNGERGGPGGPGPQGPPGKNGETGPQGPPGPTGPGGDKGDTGPPGPQGLQGLPG TGGPPGENGKPGEPGPKGDAGAPGAPGGKGDAGAPGERGPPAIAGIGGEKAGGF APYYG.

[0038] In some embodiments, the collagen fragment described herein can have an amino acid chain length from about 350 amino acids to about 600 amino acids and can have at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 9%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity, or similarity to, SEQ ID NO: 1.

[0039] In some embodiments, the recombinant collagen can comprise a hydrolysis product of a collagen fragment, wherein the hydrolyzed fragment can have a sequence that can be a portion of SEQ ID NO: 1. In some embodiments, the hydrolysis product can have a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the recombinant collagen can comprise a sequence variant of a recombinant collagen fragment having a molecular weight of about 50 kDa and a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1. Examples of such fragments and variants are disclosed, for example, inPCT / US2022 / 027016 and each such hydrolysis product having a sequence identity of about 85% to the amino acid sequence set forth in SEQ ID NO: 1 and each such sequence variant having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1 as disclosed in PCT / US2022 / 027016 is, expressly incorporated by reference herein.

[0040] In some embodiments, the lysine, proline, or lysine and proline residues present in the collagen or collagen fragment can be hydroxylated. In some embodiments, the lysine, proline, or lysine and proline residues present in the collagen fragment are not hydroxylated. In some embodiments, about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%, (or any intermediate value or subrange) of the lysine, proline, or lysine and proline residues in the recombinant collagen fragment can be hydroxylated.C. Powder Compositions and Benefits of Spray Drying

[0041] The present disclosure provides spray dried powder compositions comprising a collagen, such as the collagen of SEQ ID NO: 1, or a fragment or variant thereof, and an excipient, such as a hydrophobic amino acid. In some embodiments, the collagen can be a collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the collagen fragment can be unhydroxylated. In some embodiments, the collagen fragment can be hydroxylated.

[0042] In some embodiments, the hydrophobic amino acid and the collagen can be present in a ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 5 to about 95 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 10 to about 90 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 15 to about 85 (wt / wt). In other embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 20 to about 80 (wt / wt). In some embodiments, the collagen can be a recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1 and the hydrophobic amino acid can be leucine. In some embodiments, the collagen can be SEQ ID NO: 1 and the hydrophobic amino acid can be leucine. In some embodiments, the ratio of leucine to the recombinant collagen fragmentcan be 15:85 (wt / wt). In some embodiments, the ratio of leucine to the recombinant collagen fragment can be 20:80 (wt / wt).

[0043] Advantageously and surprisingly, using a hydrophobic amino acid to prepare the spray dried powder described herein eliminates the need for using additional excipients to manage the flow characteristics of the spray dried powder described herein. In some embodiments, the hydrophobic amino acid can be selected from the group consisting of isoleucine, leucine, valine, and phenylalanine. In some embodiments, the hydrophobic amino acid can be isoleucine. In some embodiments, the hydrophobic amino acid can be leucine. In some embodiments, the hydrophobic amino acid can be valine. In some embodiments, the hydrophobic amino acid can be phenylalanine.

[0044] In some embodiments, the spray dried powder composition can be water soluble at room temperature.

[0045] In some embodiments, the spray dried powder composition can further comprise a flow agent, and in particular a water soluble flow agent. In some embodiments, the compositions described herein do not comprise a flow agent, and in particular do not comprise a water insoluble flow agent. In some embodiments, the compositions described herein do not comprise fumed silica. In some embodiments, the compositions described herein do not comprise precipitated silica.

[0046] In some embodiments, the spray dried composition can further comprise a preservative. In some embodiments, the preservative can be potassium sorbate. In some embodiments, the preservative can be sodium benzoate. In some embodiments, the spray dried composition can comprise a pH-adjusting agent, such as, but not limited to, citric acid. The preservative and pH adjusting agents can be included in the composition alone or together, each in an amount sufficient (either alone or in concert) to provide anti-microbial activity such that the composition can be stored for an extended period of time, i.e. 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, or longer. In other embodiments, the spray dried composition can be free, or substantially free of either or both of the preservative and pH adjusting agents, but can have the above described shelflife (i.e. 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, or longer) due to one or more treatments before or during packaging that is sufficient to sterilize or otherwise kill any microbes present in the composition. In some embodiments, the treatment can comprise a heat treatment. In some embodiments, the treatment can comprise radiation treatment. In some embodiments, the treatment can comprisepasteurization. In some embodiments, the treatment can comprise a combination of any treatment provided above.

[0047] In some embodiments, the powder can have an angle of repose measurement from about 30° to about 60°. In some embodiments, the powder can have an angle of repose measurement of 48.5°. In some embodiments, the powder can have an angle of repose measurement of 50°. The angle of repose is a measurement of the steepest angle of descent or dip relative to the horizontal plane on which the material can be piled without slumping.D. Process for Preparing the Compositions Disclosed Herein

[0048] The present disclosure provides a process for preparing the spray dried composition described herein, comprising: a) preparing an aqueous mixture comprising i) a recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1; ii) a hydrophobic amino acid; and iii) deionized water, to form a feed solution; b) filtering the feed solution through a filter to form a filtered solution; and c) spray drying the filtered solution to form the powder. In some embodiments, the process further comprises pasteurization. In some embodiments, the present disclosure provides a process for preparing the spray dried composition described herein, comprising: a) preparing an aqueous mixture comprising i) a recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1; ii) a hydrophobic amino acid; and iii) deionized water, to form a feed solution; b) filtering the feed solution to form a filtered solution; c) pasteurizing the filtered solution; and d) spray drying the pasteurized solution to form the powder.

[0049] In some embodiments, a spray dried composition can be pasteurized by: a) transferring a feed solution into a jacketed tank; b) agitating the solution; c) heating the solution in the jacketed tank to a temperature suitable for pasteurizing the solution; d) holding the solution at the temperature for a period of time sufficient to pasteurize the solution; and e) cooling the solution. In some embodiments, the solution can be heated to a temperature from about 60 °C to about 95 °C. In some embodiments, the solution can be heated for a time from about 5 minutes to about 60 minutes. In certain embodiments, the filtered solution can be pasteurized for about 15 seconds at about 130 °C.

[0050] In some embodiments, the hydrophobic amino acid and the collagen can be present in a ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 5 toabout 95 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 10 to about 90 (wt / wt). In some embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 15 to about 85 (wt / wt). In other embodiments, the ratio of the hydrophobic amino acid to the collagen can be about 20 to about 80 (wt / wt).

[0051] In some embodiments, the sieve can have a mesh size from about 0.01 mm to about 1 mm. In some embodiments, the sieve can have a mesh size of about 0.5 mm.

[0052] In some embodiments, the spray drying apparatus can have a nozzle diameter from about 0.1 mm to about 1.5 mm. In some embodiments, the spray drying apparatus can have a nozzle diameter of about 0.7 mm.

[0053] In some embodiments, the spray drying apparatus can have an inlet temperature from about 180 °C to about 240 °C. In some embodiments, the spray drying apparatus can have an inlet temperature of 220 °C.

[0054] In some embodiments, the spray drying apparatus can have an outlet temperature from about 80 °C to about 160 °C. In some embodiments, the spray drying apparatus can have an outlet temperature of about 140 °C.

[0055] In some embodiments, the spray drying apparatus can have a drying air flow rate from about 100 m3 / hr to about 6000 m3 / hr. In some embodiments, the spray drying apparatus can have a drying air flow rate of about 346 m3 / hr.

[0056] In some embodiments, the spray drying apparatus can have a liquid feed rate from about 0.5 kg / hr to about 500 kg / hr. In some embodiments, the spray drying apparatus can have a liquid feed rate of about 2 kg / hr.

[0057] In some embodiments, spray drying apparatus can have an atomizing air pressure from about 0.1 bar to about 100 bar. In some embodiments, the spray drying apparatus can have an atomizing air pressure of 1.9 bar.

[0058] In some embodiments, the process can further comprise an antimicrobial treatment. In some embodiments, the antimicrobial treatment can comprise dry heat treatment.

[0059] In some embodiments, the compositions described herein can be prepared by the processes described above. In some embodiments, the composition can have a spray drying yield from about 80% to about 100%, wherein the spray drying yield is calculated as the percentage of the mass of the powder recovered from spray drying from the total mass of solids content of the feed solution. In some embodiments, the composition can have pharmaceutically acceptable and cosmetically acceptable flow characteristics.E. Methods of Use

[0060] The powder compositions disclosed herein can be beneficially formulated for uses that include but are not limited to: pharmaceutical compositions formulated for any route of administration including intranasal, oral (e.g., tablets or capsules), parenteral, intrathecal, intra-cerebroventricular, pulmonary, subcutaneous, or intraventricular. Injectables that include the powder compositions disclosed herein can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

[0061] Preparations for parenteral administration include sterile dry soluble powder products that are ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.

[0062] Topical mixtures comprising the powder compositions described herein can be prepared for local and systemic administration. The resulting mixture can be a solution, suspension, emulsions or the like and can be formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

[0063] The compositions described herein described herein can also be formulated as an aerosol for topical application, such as by inhalation.Examples

[0064] The examples presented below are provided for the purpose of illustration only and the embodiments described herein should in no way be construed as being limited to these examples. Rather, the embodiments should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.Examples: Spray Drying of Recombinant Collagen with Leucine

[0065] The amino acid sequence of SEQ ID NO: 1 was formulated with various amounts of leucine. In the examples below, the phrase “feed solution” refers to an aqueous solution of the recombinant collagen and leucine. The composition of the feed solutions is expressedas weight percentage of each solute. For example, a 2000 gram feed solution comprising 10 wt% SEQ ID NO. 1 has 200 grams of SEQ ID NO. 1 as a solute.

[0066] A “Lab2” spray dryer manufactured by Hemraj Engineering (Mumbai) was used in a 2-collection point configuration with powder settling in the cyclone and baghouse. A two fluid co-current nozzle was used to atomize the liquid feed. The yields reported below only consider product collected from the cyclone.Example 1: Excipient-free Spray Drying of SEQ ID NO. 1

[0067] 4160 grams of an aqueous feed solution comprising 11.25 wt% SEQ ID NO: 1 was spray dried using the operating parameters shown in Table 1.Table 1

[0068] Spray dried powder (335 grams) was collected from the cyclone, corresponding to a 76% yield by mass. The powder was adhesive and hygroscopic. The powder had an angle of repose measurement of 60°, indicating “very poor” flow characteristics.Example 2: Spray Drying with a 20:80 ratio of Leucine:SEQ ID NO: 1

[0069] 2201 grams of an aqueous solution comprising 11.38 wt% SEQ ID NO: 1 was added to 585 grams of deionized water. Leucine (62.6 grams) was added to this mixture, and the resulting mixture was then filtered through a 0.5 mm sieve. The solids content of the resulting solution was 10.2%. The solution (2273 grams) was then spray dried using the operating parameters shown in Table 1.

[0070] A total of 210 grams of powder was collected from the cyclone, corresponding to 91% yield by mass. The powder had an angle of repose measurement of 48.5°, indicating improved flow characteristics relative to SEQ ID NO: 1 powder without excipient. The powder also had acceptable flow characteristics.

[0071] The resulting powder was analyzed by Size Exclusion Chromatography (SEC) and the results are shown in FIG. 1 A. For the SEC analysis, 1 part of the powder was dissolved in 99 parts water to form a 1% solution. The SEC trace for the spray dried product overlapped with the SEC trace for the spray drying feed. The small spray dried product peak at 11.5 minutes retention time resulted from leucine. The similarity between the peak profile of the spray dried product and the spray drying feed solution indicated that there was minimal change in product integrity during spray drying. The difference in peak heights is due to the difference in sample concentrations.Example 3: Spray Drying with a 6:94 ratio of Leucine:SEQ ID NO: 1

[0072] 2125 grams of an aqueous solution comprising 12.01 wt% SEQ ID NO: 1 was mixed with 17 grams of leucine. The resulting mixture was then filtered through a 0.5 mm sieve. The solids content of the filtered solution was 12.47%. The filtered solution (2052 grams) was spray dried with the operating parameters shown in Table 1. A total of 229 grams of powder was collected from the cyclone, corresponding to 89% yield by mass. The powder had an angle of repose measurement of 58.5°, indicating “very poor” flow characteristics.Example 4: Spray drying with a 10:90 ratio of Leucine: SEQ ID NO: 1

[0073] 2260 grams of an aqueous solution comprising 12.01 wt% SEQ ID NO: 1 was mixed with 32 grams of leucine. The resulting mixture was then filtered through a 0.5 mm sieve. The solids content of the filtered solution was 13.06%. The filtered solution (2155 grams) was spray dried using the operating parameters shown in Table 1. A total of 241.4 grams of powder was collected from the cyclone, corresponding to 86% yield by mass. The powder had an angle of repose measurement of 57°, which indicates “very poor” flow characteristics.Example 5: Spray Drying with a 15:85 ratio of Leucine: SEQ ID NO: 1

[0074] 2240 grams of an aqueous solution comprising 11.14 wt% SEQ ID NO: 1 was added to 205 grams of deionized water. Leucine (43.9 grams) was added to this mixture, and the resulting mixture was then filtered through a 0.5 mm sieve. The solids content of the filtered solution was 11.73%. The filtered solution (2225 grams) was spray dried using the operating parameters shown in Table 1. A total of 231 grams of powder was collected fromthe cyclone, corresponding to 88.5% yield by mass. The powder had an angle of repose measurement of 50°, indicating less stickiness relative to SEQ ID NO: 1 powder without an excipient, and acceptable flow characteristics.

[0075] The resulting powder was analyzed by Size Exclusion Chromatography (SEC) and the results are shown in FIG. IB. For the SEC analysis, 1 part of the powder was dissolved in 99 parts water to form a 1% solution. The SEC trace for the spray dried product overlapped with the SEC trace for the spray drying feed. The small spray dried product peak at 11.5 minutes retention time resulted from leucine. The similarity between the peak profile of the spray dried product and the spray drying feed solution indicated that there was minimal change in product integrity during spray drying. The difference in peak heights is due to the difference in sample concentrations.Example 6: Spray Drying with Preservative followed by Dry-Heat Treatment

[0076] 0.35 grams of potassium sorbate was added to 1000 grams of an aqueous solution comprising 11.5 wt% SEQ ID NO: 1. 6.4 grams of a 10% (wt / wt) citric acid solution was added to lower the pH of the mixture to 6.0-6.1. The solution was then spray dried with the operating parameters shown in Table 1.

[0077] A total of 92 grams of powder was collected from the cyclone, corresponding to 79% yield by mass. A portion of this powder was vacuum packed in a Mylar bag. The bag was then placed in an oven at 95 °C for 90 minutes.

[0078] Bioburden was measured before and after heat treatment. Bioburden in a comparative example that did not contain any preservative was likewise measured. These results are shown in Table 2.Table 2

[0079] It is to be appreciated that the Detailed Description section, and not the Summary and Abstract sections, is intended to be used to interpret the claims. The Summary and Abstract sections may set forth one or more but not all exemplary embodiments of the present invention as contemplated by the inventor(s), and thus, are not intended to limit the present invention and the appended claims in any way.

Claims

WHAT IS CLAIMED IS:

1. A spray dried composition comprising a recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1 and a hydrophobic amino acid, wherein the composition is a powder.

2. The spray dried composition of claim 1, wherein the recombinant collagen fragment is unhydroxylated.

3. The spray dried composition of claim 1, wherein the recombinant collagen fragment is hydroxylated.

4. The spray dried composition of any one of claims 1-3, wherein the hydrophobic amino acid and the recombinant collagen fragment are present in the composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt).

5. The spray dried composition of claim 4, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 5:95.

6. The spray dried composition of claim 4, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 10:90.

7. The spray dried composition of claim 4, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 15:85.

8. The spray dried composition of claim 4, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 20:80.

9. The spray dried composition of any one of claims 1-8 wherein the hydrophobic amino acid is leucine.

10. The spray dried composition of claim 9, wherein the leucine and the recombinant collagen fragment are present in the composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt).

11. The spray dried composition of claim 10, wherein the ratio of the leucine to the recombinant collagen fragment is about 5:95.

12. The spray dried composition of claim 10, wherein the ratio of the leucine to the recombinant collagen fragment is about 10:90.

13. The spray dried composition of claim 10, wherein the ratio of the leucine to the recombinant collagen fragment is about 15:85.

14. The spray dried composition of claim 10, wherein the ratio of the leucine to the recombinant collagen fragment is about 20:80.

15. The spray dried composition of any one of claims 1-8, wherein the hydrophobic amino acid is selected from the group consisting of isoleucine, leucine, valine, and phenylalanine.

16. The spray dried composition of claim 15, wherein the hydrophobic amino acid is isoleucine.

17. The spray dried composition of claim 15, wherein the hydrophobic amino acid is valine.

18. The spray dried composition of claim 15, wherein the hydrophobic amino acid is phenylalanine.

19. The spray dried composition of any one of claims 1-18, wherein the spray dried powder is water soluble at room temperature.

20. The spray dried composition of any one of claims 1-19, wherein the spray dried powder further comprises a flow agent.

21. The spray dried composition of any one of claims 1-19, wherein the spray dried powder does not comprise a flow agent.

22. The spray dried composition of any one of claims 1-21, wherein the composition further comprises a preservative.

23. The spray dried composition of claim 22, wherein the preservative is potassium sorbate.

24. The spray dried composition of claim 22, wherein the preservative is sodium benzoate.

25. The spray dried composition of any one of claims 1-24, wherein the composition comprises a pH-adjusting agent.

26. The spray dried composition of claim 25, wherein the pH-adjusting agent is citric acid.

27. The spray dried composition of any one of claims 1-25, wherein the powder has an angle of repose of about 30° to about 60°.

28. The spray dried composition of claim 27, wherein the powder has an angle of repose of about 48.5°.

29. The spray dried composition of claim 27, wherein the powder has an angle of repose of about 50°.

30. A process for preparing the spray dried composition of claim 1, comprising: a) preparing an aqueous mixture comprising the recombinant collagen fragment having a sequence identity of at least about 85% to the amino acid sequence set forth in SEQ ID NO: 1, the hydrophobic amino acid, and deionized water, to form a feed solution; b) filtering to form a filtered solution; and c) spray drying the filtered solution to form the powder.

31. The process of claim 30, further comprising pasteurization.

32. The process of claim 30 or 31, wherein the hydrophobic amino acid and the recombinant collagen fragment are present in the spray dried composition in a weight ratio ranging from about 1 to about 99 (wt / wt) to about 30 to about 70 (wt / wt).

33. The process of any one of claims 30-32, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 5:95.

34. The process of any one of claims 30-32, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 10:90.

35. The process of any one of claims 30-32, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 15:85.

36. The process of any one of claims 30-32, wherein the ratio of the hydrophobic amino acid to the recombinant collagen fragment is about 20:80.

Citation Information

Patent Citations

  • Recombinant gelatins

    US20050229264A1

  • Broth compositions and their use as prebiotics

    US20160213752A1

  • Pure Collagen Milk Powder and Preparation Method Thereof

    US20190281851A1

  • Animal-free dietary collagen

    WO2021150959A1

  • Skincare compositions and methods of use thereof

    WO2022170114A1